Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Development and Characterisation of an in Vitro Model of Multiple Myeloma

Thomas Lewis, BSc, Elisabeth Jane Walsby, PhD, Stephen Man, Christopher Fegan, Chris Pepper, BSc, PhD

Blood (2018) 132 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2018-99-111842

Published: 2018

Journal Articles

Acute Myeloid Leukemia Expands Osteoprogenitor Rich Niche in the Bone Marrow but Resorbs Mature Bone Causing Osteopenia/Osteoporosis in Animal Models

Bin Yuan, Stanley Ly, Khoa Nguyen, Vivien Tran, Kiersten Maldonado, Charles Kinglsey, Jared K Burks, PhD, Xin Zhou, PhD, Benoit deCrombrugghe, Michael Andreeff, MD PhD, Venkata Lokesh Battula, PhD

Blood (2018) 132 (Supplement 1): 86.

https://doi.org/10.1182/blood-2018-99-117258

Published: 2018

Journal Articles

The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia

Panagiotis Anagnostis, Sofia Vakalopoulou, Dimitrios Christoulas, Spyridon Karras, Athanasios Papatheodorou, Eirini Katodritou, Panagiotis Kokkoris, Vasilia Garipidou, Evangelos Terpos

Blood (2015) 126 (23): 2284.

https://doi.org/10.1182/blood.V126.23.2284.2284

Published: 2015

Journal Articles

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Marita Westhrin, MSc, Siv Helen Moen, PhD, Toril Holien, PhD, Oddrun Elise Olsen, MSc, Anne Kærsgaard Mylin, MDhD, Peter Gimsing, MD PhD, Ingemar Turesson, MD PhD, Anders Waage, MD PhD, Therese Standal, PhD

Blood (2014) 124 (21): 2065.

https://doi.org/10.1182/blood.V124.21.2065.2065

Published: 2014

Journal Articles

Age and Sex Determinants of Bone Phenotype in a Transgenic Mouse Model of Sickle Cell Disease

Idowu Akinsheye Akinsanmi, PhD, Angela Lin, Robert Guldberg, PhD, Manu Platt, PhD, Gilda Barabino, PhD

Blood (2012) 120 (21): 3249.

https://doi.org/10.1182/blood.V120.21.3249.3249

Published: 2012

Journal Articles

Targeting CD26 with Humanized Monoclonal Antibody, As a Novel Approach to Inhibit Human Osteoclast Differentiation and Subsequent Bone Resorption

Hiroko Nishida, MD., PhD., Hiroko Madokoro, Hiroshi Suzuki, Michiie Sakamoto, M.D., Ph.D., Chikao Morimoto, M.D., Ph.D., Taketo Yamada, MD, PhD

Blood (2012) 120 (21): 1348.

https://doi.org/10.1182/blood.V120.21.1348.1348

Published: 2012

Journal Articles

Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease

Marco Rossi, MD, Maria Rita Pitari, PhD student, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Emanuela Leone, PhD, Francesco Conforti, MD, Francesco Maria Paolino, PhD student, Cirino Botta, MD, Teresa Del Giudice, MD, Eleonora Iuliano, MD, Manlio Ferrarini, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2012) 120 (21): 3960.

https://doi.org/10.1182/blood.V120.21.3960.3960

Published: 2012

Journal Articles

Skeletal Effects of the Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib in Young Rats

Josephine Tabea Tauer, Lorenz C. Hofbauer, Reinhold G. Erben, Meinolf Suttorp, MD

Blood (2012) 120 (21): 4429.

https://doi.org/10.1182/blood.V120.21.4429.4429

Published: 2012

Journal Articles

Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable ONX 0912 Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects

Michelle A Hurchla, Antonio Garcia-Gomez, Mary C Hornick, Enrique M Ocio, Aixiao Li, Juan F Blanco, Lynne Collins, Christopher J Kirk, David Piwnica-Worms, Ravi Vij, MD, Michael H Tomasson, Atanasio Pandiella, Jesús F San Miguel, Mercedes Garayoa, Katherine N Weilbaecher

Blood (2011) 118 (21): 2906.

https://doi.org/10.1182/blood.V118.21.2906.2906

Published: 2011

Journal Articles

Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study

Konstantinos Anargyrou, Theodoros P. Vassilakopoulos, Konstantinos Tsionos, Panayiotis Kokkoris, Georgios Boutsikas, Maria K. Angelopoulou, Dimitrios Christoulas, Stavroula Masouridou, Maria Dimou, Athanasios Papatheodorou, Danos N. Chatzifotiadis, Panayiotis Panayiotidis, Gerasimos A. Pangalis, Photis Beris, Evangelos Terpos

Blood (2010) 116 (21): 5071.

https://doi.org/10.1182/blood.V116.21.5071.5071

Published: 2010

Journal Articles

High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia

Ersi Voskaridou, Dimitrios Christoulas, Athanasios Papatheodorou, Cornelia Bratengeier, Eleni Plata, Despoina Kaliontzi, Wolfgang Woloszczuk, Evangelos Terpos

Blood (2010) 116 (21): 1010.

https://doi.org/10.1182/blood.V116.21.1010.1010

Published: 2010

Journal Articles

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

Antonio Garcia-Gomez, Mercedes Garayoa, Enrique M. Ocio, Edvan Crusoe, Diego Fernández, Teresa Paíno, Laura San Segundo, Juan C. Montero, Stela Álvarez-Fernández, Juan F. Blanco, Fermin M. Sanchez-Guijo, Felix T. Garzon, Atanasio Pandiella, Jesús F. San-Miguel, MD, PhD

Blood (2009) 114 (22): 3834.

https://doi.org/10.1182/blood.V114.22.3834.3834

Published: 2009

Journal Articles

First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).

Blood (2009) 114 (22): 1951.

https://doi.org/10.1182/blood.V114.22.1951.1951

Published: 2009

Journal Articles

Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients

Evangelos Terpos, Meletios A. Dimopoulos, Vikas Shrivastava, Kim Leitzel, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Konstantinos Anargyrou, Efstathios Kastritis, Allan Lipton

Blood (2008) 112 (11): 5143.

https://doi.org/10.1182/blood.V112.11.5143.5143

Published: 2008

Journal Articles

Pharmacological Chaperone Therapy for the Treatment of Gaucher Disease: Results of Phase 1 Clinical Trials and a Clinical Ex Vivo Response Study with a Survey of Blood Markers for 53 Gaucher Patients.

Neal J. Weinreb, MD, G.A. Grabowski, MD, G.M. Pastores, MD, P.M. Fernhoff, MD, P.B. Kaplan, MD, D. Palling, PhD, C.W. Pine, B.E. Raines, F. Insinga, D.J. Lockhart, PhD, H.V. Do, PhD, B.A. Wustman, PhD

Blood (2007) 110 (11): 2404.

https://doi.org/10.1182/blood.V110.11.2404.2404

Published: 2007

Journal Articles

The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.

Evangelos Terpos, Sosana Delimpasi, Konstantinos Anargyrou, Ioannis Baltathakis, Efstathios Kastritis, Anna Christoforidou, Konstantinos Tsionos, Konstantinos Tsatalas, Emmanuel Nikiforakis, Meletios A. Dimopoulos, Nikolaos Harhalakis

Blood (2007) 110 (11): 3596.

https://doi.org/10.1182/blood.V110.11.3596.3596

Published: 2007

Journal Articles

Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693.

Todd A. Hembrough, Xiaoru Chen, Patricia A. Burke, Glenn M. Swartz, Kathleen Bengali, Richard Brokx, Theresa M. LaVallee, Mark R. Bray

Blood (2007) 110 (11): 1209.

https://doi.org/10.1182/blood.V110.11.1209.1209

Published: 2007

Journal Articles

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.

Evangelos Terpos, Athanasios Anagnostopoulos, Deborah Heath, Efstathios Kastritis, Dimitrios Christoulas, Nikolaos Anagnostopoulos, Maria Roussou, Konstantinos Tsionos, Peter Croucher, Meletios A. Dimopoulos

Blood (2006) 108 (11): 3541.

https://doi.org/10.1182/blood.V108.11.3541.3541

Published: 2006

Journal Articles

Peripheral Blood Cells from Multiple Myeloma Patients Show Increased Osteoclast and Decreased Osteoblast Gene Expression.

Melinda S. Gordon, PhD, Ariana M. Berenson, Charles B. Drucker, Matthew Katz, Hee Jin Lee, BS, Richard A. Campbell, BS, Haiming Chen, MD, PhD, Howard S. Yeh, MD, Benjamin Bonavida, PhD, Jonathan Said, MD, James R. Berenson, MD

Blood (2005) 106 (11): 5098.

https://doi.org/10.1182/blood.V106.11.5098.5098

Published: 2005

Journal Articles

Establishment and Characterization of a New Human Myeloma Cell Line WuS1.

Wanling Sun, MD, PhD, Yongji Wu, MD, PhD, Hui Li, Xuan Wang, BM, Nong Zou, BM, Junling Zhuang, MD, PhD

Blood (2005) 106 (11): 5114.

https://doi.org/10.1182/blood.V106.11.5114.5114

Published: 2005

NARROW

Development and Characterisation of an in Vitro Model of Multiple Myeloma

Acute Myeloid Leukemia Expands Osteoprogenitor Rich Niche in the Bone Marrow but Resorbs Mature Bone Causing Osteopenia/Osteoporosis in Animal Models

The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Age and Sex Determinants of Bone Phenotype in a Transgenic Mouse Model of Sickle Cell Disease

Targeting CD26 with Humanized Monoclonal Antibody, As a Novel Approach to Inhibit Human Osteoclast Differentiation and Subsequent Bone Resorption

Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease

Skeletal Effects of the Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib in Young Rats

Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable ONX 0912 Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects

Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study

High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).

Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients

Pharmacological Chaperone Therapy for the Treatment of Gaucher Disease: Results of Phase 1 Clinical Trials and a Clinical Ex Vivo Response Study with a Survey of Blood Markers for 53 Gaucher Patients.

The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.

Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693.

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.

Peripheral Blood Cells from Multiple Myeloma Patients Show Increased Osteoclast and Decreased Osteoblast Gene Expression.

Establishment and Characterization of a New Human Myeloma Cell Line WuS1.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only